Early diagnosis allows doctors to slow the disease's progression
Em um país onde o envelhecimento populacional avança e o Alzheimer afeta milhões de famílias, um laboratório brasileiro deu um passo significativo ao introduzir um exame de sangue capaz de detectar a doença em seus estágios mais precoces. A Dasa trouxe ao Brasil uma tecnologia semelhante à aprovada pela FDA americana, que identifica placas amiloides — marcadores biológicos do Alzheimer — antes que o declínio cognitivo se torne severo. É um avanço que não cura, mas que abre uma janela de tempo: tempo para planejar, para tratar, para viver com mais dignidade.
- O Alzheimer avança silenciosamente, e o diagnóstico tardio ainda priva milhares de pacientes brasileiros da chance de retardar a progressão da doença.
- A Dasa lança um exame de sangue que detecta proteínas beta-amiloide por espectrometria de massa, trazendo ao Brasil uma tecnologia antes restrita a centros médicos americanos.
- Médicos e famílias ganham uma nova ferramenta para agir na janela crítica do comprometimento cognitivo leve, quando intervenções ainda podem fazer diferença real na qualidade de vida.
- Apesar da inovação, neurologistas alertam que cerca de 80% dos diagnósticos ainda dependem de avaliação clínica tradicional — exame físico, histórico do paciente e testes neuropsicológicos.
- O exame chega não como uma revolução, mas como uma expansão do arsenal diagnóstico: mais uma forma de confirmar suspeitas clínicas e identificar quem mais se beneficiaria de intervenção precoce.
Um laboratório brasileiro deu um passo relevante no diagnóstico do Alzheimer ao lançar um exame de sangue capaz de identificar a doença antes que o declínio cognitivo se torne grave. A Dasa introduziu no Brasil uma tecnologia semelhante à recentemente aprovada pela FDA americana: o exame detecta placas amiloides, acúmulos de proteína que danificam células cerebrais e são uma marca registrada da patologia do Alzheimer.
O exame funciona por espectrometria de massa, uma técnica laboratorial que identifica moléculas em concentrações mínimas. A partir de uma amostra de sangue, é possível medir dois tipos específicos de proteína beta-amiloide — as formas 40 e 42. Gustavo Campana, diretor médico da Dasa, destacou que o diagnóstico precoce permite retardar a progressão da doença e oferece a pacientes e familiares mais tempo para se organizar e adaptar, preservando a qualidade de vida de todos os envolvidos.
O Alzheimer não tem cura, mas a detecção em estágios iniciais — quando o paciente apresenta apenas comprometimento cognitivo leve ou quando a demência ainda é uma suspeita — muda o curso da doença. É justamente nessa janela de oportunidade que o novo exame atua.
Ainda assim, o neurologista Ivan Okamoto lembra que em cerca de quatro de cada cinco casos, o diagnóstico ainda se apoia nos métodos tradicionais: exame físico, histórico clínico detalhado, exames de sangue para excluir outras condições e avaliação neuropsicológica. A chegada do exame ao Brasil representa uma ampliação das opções diagnósticas — não uma substituição do olhar clínico, mas um reforço a ele, especialmente para pacientes com sinais precoces que podem se beneficiar de intervenção imediata.
A Brazilian laboratory has introduced a blood test designed to catch Alzheimer's disease earlier, before the cognitive decline becomes severe. The test, launched by Dasa, looks for amyloid plaques—sticky protein accumulations that damage brain cells and are a hallmark of Alzheimer's pathology. The approach mirrors technology the U.S. Food and Drug Administration recently approved, bringing a method once available mainly in American medical centers within reach of Brazilian patients.
Alzheimer's remains incurable, but researchers have long understood that earlier detection changes the trajectory of the disease. If caught when a patient is experiencing only mild cognitive impairment or when dementia is merely suspected, treatment can slow the disease's progression and give patients and their families more time to plan and adapt. The new blood test targets this window of opportunity by identifying two specific forms of beta-amyloid protein—types 40 and 42—using a laboratory technique called mass spectrometry, which can detect molecules present in tiny concentrations.
The process is straightforward: a patient provides a blood sample, and the laboratory runs it through mass spectrometry to measure amyloid levels. Gustavo Campana, the medical director at Dasa, framed the advance in terms of patient outcomes. Early diagnosis, he explained, allows doctors to slow how quickly the disease advances and gives families better control over symptoms, ultimately preserving quality of life for both the person with Alzheimer's and those caring for them.
Yet the arrival of this test in Brazil also highlights how complex Alzheimer's diagnosis remains. Despite the promise of biomarker detection, neurologist Ivan Okamoto noted that in roughly four out of five cases, doctors still rely on traditional methods: a thorough physical examination, a detailed patient history, blood work to rule out other conditions, and neuropsychological testing to quantify memory complaints. These clinical tools remain the backbone of diagnosis, and they cannot be easily replaced by a single blood test.
The test's introduction to Brazil represents an expansion of diagnostic options rather than a revolution in how the disease is identified. For patients showing early signs of cognitive trouble, it offers a new way to confirm what clinical suspicion already suggests. For the broader medical system, it means another tool in the diagnostic arsenal—one that may help identify people who would benefit most from early intervention, even as the majority of Alzheimer's cases will continue to be diagnosed the way they have been for decades: through careful clinical observation and assessment.
Notable Quotes
Early diagnosis allows doctors to slow disease progression and gives patients and families better control over symptoms, preserving quality of life— Gustavo Campana, medical director at Dasa
In roughly 80% of cases, Alzheimer's is diagnosed through physical examination, patient history, blood work to rule out other conditions, and neuropsychological testing— Ivan Okamoto, neurologist
The Hearth Conversation Another angle on the story
Why does a blood test matter if doctors can already diagnose Alzheimer's through physical exams and memory testing?
Because those traditional methods catch the disease after damage is already visible. A blood test can find the amyloid plaques years earlier, when the person still functions normally but the disease is silently progressing.
So it's about timing—getting ahead of the symptoms?
Exactly. Once symptoms show up, the brain has already lost significant function. If you can slow the disease before that happens, you buy the patient and family years of better quality of life.
But the article says 80% of cases are still diagnosed clinically. Does that mean this test won't change much?
It changes things for the people who get tested early, before they're obviously sick. But you're right that most Alzheimer's is still caught late, when someone comes to a doctor with memory problems. This test is for the people worried enough to get screened, or whose doctors suspect something early.
Who benefits most from this?
People in the early stages—mild cognitive impairment, subtle changes family members notice. For them, this test can confirm what's happening and start treatment sooner. For someone already showing clear dementia symptoms, the clinical diagnosis is usually obvious enough.